Communications for brands + leaders at the intersection of healthcare, science + technology | Ex-Recursion, Amwell, Moderna
It pains me a little as their former communications lead to admit it, but this is the best story written on Recursion to-date. STAT reporter Allison DeAngelis nailed it; the early skepticism, Founder-CEO Chris Gibson's "intense" and indomitable spirit, and importantly, the differences between Recursion's first shots on goal and the rest of the pipeline to come. Excerpt: ---The market, which initially had stratospheric expectations for AI drug development, has become somewhat skeptical of this first generation of candidates following early failures at Exscientia and another firm called Benevolent AI. Powers, the ZS Associates partner, said that Recursion has likely been stressing in public statements that it has 10 data readouts planned for the next 18 months so that it isn’t judged too harshly on the first two or three. “Of course we’re hedging,” Gibson said. “I’m ready for the volatility that will inevitably come…. Nobody’s going to get 10 out of 10.”--- A must read for anyone in the #AI #pharma sector.
